US 10849919

I'll search for current information on this patent, including USPTO records and any CAFC 2026 docket activity.

Let me search specifically for any 2026 Federal Circuit activity and the patent's claim set.

Summary — US Patent No. 10,849,919 (interpreted literally as "10849919")

Important note on scope of this answer: I identified no Federal Circuit (CAFC) 2026 docket involving US 10,849,919. Search results for "CAFC 2026" return unrelated matters (e.g., a Sanofi/Ablynx appeal concerning U.S. Application No. 17/409,019 — a different "019" identifier; Nintendo/Gamevice; Apple/SpaceTime3D). Per your instruction, I have not conflated those with US 10,849,919. The PTAB proceeding that challenged this patent settled before a final written decision, so it generated no statutory CAFC appeal. I flag this as "not found" rather than "none exists," since I cannot exhaustively query PACER/CAFC dockets.

Bibliographic data (from the patent front page and corroborating sources)

Certificate of Correction (signed Oct. 25, 2022): corrected the specification's priority statement from "Nov. 24, 2018" to "Nov. 24, 2017," and corrected claim 6's dependency from "according to claim 4" to "according to claim 5."

Family/continuations: 22 family members in 14 countries. US continuations with priority to this family include US 16/949,278 → US 12,268,703 B2; US 17/932,796 → US 2023/0021880 A1; and US 19/069,698 → US 2025/0241938 A1. Foreign members include Australia 2018372007 and 2024227421, Brazil 112020010282, and Argentina 113906.

Abstract (verbatim)

"Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine."

Plain-language overview of the independent claims

The claims are method/use claims directed to oral cladribine dosed at a "fixed dose" calculated per patient, per body weight, and per treatment year, for progressive MS. Based on the specification and on the IPR2023-00482 petition and patent-owner response (which quote the claims), the independent claims appear to be at least claims 1, 14, 24, 27 (and possibly 33/34):

• Claim 1 — A method of treating a progressive form of MS selected from SPMS, PPMS, and PRMS, expressly excluding Early Secondary Progressive MS (ESPMS), comprising orally administering cladribine (quoted preamble from Ex. 1001 at col. 64:45–57; the body recites the fixed-dose per-patient/per-body-weight/per-treatment-year limitation, consistent with the '919 specification sections 1–3). The full body text is not verbatim in my sources; treat this as an inference from the specification and the IPR record.
• Claim 14 — A method of treating progressive MS by oral cladribine over 2 treatment courses in 2 years (roughly 3.5 mg/kg cumulative; ~1.75 mg/kg per year), each course comprising two treatment weeks — one at the start of month 1 and one at the start of month 2 — at 10 or 20 mg/day. Dependent claims 18–23 add: SPMS/PPMS selection (18); 4–5 days per week at 10/20 mg (19); age 18–65 (20); co-administration of another DMD (21); interferon co-therapy (22); and no cladribine in the 1–2 years after the two courses (23).
• Claim 24 — A method of treating a progressive form of MS with ~10 mg cladribine tablets/capsules given as a 2-month treatment course (daily 10 or 20 mg for 3–6 days per month), followed by a 10-month cladribine-free period, where the number of tablets per week is assigned by body-weight bands (e.g., 40–<50 kg → 4 then 4 tablets; 100–<110 kg → 10 then 9 tablets; etc.).
• Claim 27 — Cladribine for use in the oral treatment of PPMS and/or SPMS patients at a fixed dose of 1.75 mg/kg per treatment year ± 0.2 mg/kg, over at least two (preferably two or three) treatment years.
• Claims 33 and 34 — Additional independent claims in the same family. The IPR petition addressed claim 34 separately and grouped 33 with 11/23 under an additional ground. I do not have authoritative verbatim text for claims 33 and 34 and will not reconstruct them. Also note claim 30 was challenged in IPR Ground 3.

The Orange Book "use" statement corroborates the narrowest commercial scope: "TREATING NON-EARLY SPMS BY ADMINISTERING ORAL CLADRIBINE AT A FIXED DOSE PER PATIENT, PER BODY WEIGHT AND PER TREATMENT YEAR, WHICH FIXED DOSE IS 1.75 +/- 0.2 MG/KG, TO BE ADMINISTERED WITHIN MONTHS 1 AND 2 IN EACH OF 2 ADJACENT TREATMENT YEARS."

Litigation / PTAB (as of the retrieved sources)

• D. Del. 1:22-cv-01365 (Merck KGaA et al. v. Hopewell Pharma Ventures, Inc.), filed Oct. 17, 2022 — asserts the '919 patent (along with US 7,713,947 and US 8,377,903) against Hopewell; also named Apotex, Aurobindo entities. (Unified Patents lists case 1:22-cv-01365.)
• D. Del. 1:23-cv-00039 (Merck KGaA et al. v. Aurobindo Pharma USA, Inc. et al.) — '919 and '903 patents asserted.
• D. Del. 1:22-cv-00974 (Merck KGaA et al. v. Accord Healthcare, Inc. et al.) — '919 and '903 patents asserted.
• D. Del. 1:23-cv-00655 (Merck KGaA et al. v. Apotex Inc. et al.) — ANDA No. 218425; asserted claims of the '919 patent include at least claims 1, 14, and 27.
• PTAB IPR2023-00482 (Hopewell Pharma Ventures, Inc. et al. v. Ares Trading S.A.), filed Feb. 10, 2023 — challenged claims 1–6, 8–9, 11–12, 14–16, 18–20, 23–27, 30, and 33–34 on obviousness over Alvarez-Gonzalez + Giovannoni (Ground 1), further with Montalban (Ground 2), and over ClinicalTrials.gov + Schreiber + Giovannoni (Ground 3). Status: Terminated–Settled, Aug. 16, 2023 (no FWD). A companion IPR2023-00481 challenged the related '903 patent.
• CAFC 2026: No appeal involving US 10,849,919 was identified. Because IPR2023-00482 settled pre-institution/FWD, there is no PTAB final decision to appeal; any 2026 appellate activity would most plausibly arise from the Delaware ANDA actions, and I found none.

Uncertainty flags

• The exact wording of independent claims 1, 33, and 34 is not fully quoted in my sources; I have confined my description to verbatim-quoted fragments and clearly labeled inferences.
• The patent's specification contains numbered "Sections" that read like claims; these are not necessarily identical to the granted claims, which were quoted in the IPR at col. 64:45 onward.
• Court-case status details (present-day docket entries for the Delaware actions) are sourced from secondary databases (Unified Patents, Docket Alarm, DrugPatentWatch, CourtListener/ParaGraph4), not direct USPTO/PACER retrieval in this session.

I'll search for litigation involving US 10,849,919 specifically.

Let me dig into the specific district court cases and their statuses.

Let me verify the other Delaware case and confirm the '919 patent's status in each.

Answer: Yes — US 10,849,919 has known litigation, but in every matter it was either dropped or settled before decision

I searched litigation-focused sources (D. Del. dockets via the court's own opinion PDFs and DrugPatentWatch/Stanford NPE/Unified data) plus PTAB records for the exact patent number 10,849,919. All hits resolve to the same Mavenclad® (cladribine) Hatch-Waxman campaign. There is no Federal Circuit case whose subject patent is the '919 patent — a point I flag explicitly below, because the well-publicized 2025–2026 Merck appellate losses concern different patents in the same family.

Litigation involving US 10,849,919

Sources: D. Del. Report & Recommendation in 22-1365 (https://www.ded.uscourts.gov/sites/ded/files/opinions/22-1365.pdf); Accord First Amended Complaint (https://www.docketalarm.com/cases/PTAB/IPR2023-00050/TWi_Pharmaceuticals_Inc/docs/10-14-2022-Petitioner/Exhibit-1010-Merck_Complaint.pdf); FDA ANDA 218425 approval letter (https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/218425Orig1s000ltr.pdf); IPR2023-00482 docket (https://ipverse.greyb.com/ptab-web/cases/case-details/IPR2023-00482).

Critical caveats that change the picture

1. The '919 patent was affirmatively withdrawn from every district court case that named it. The Delaware court's Report and Recommendation (22-1365) states verbatim: "Plaintiffs previously also asserted a third patent in these consolidated cases: United States Patent No. 10,849,919 (the '919 patent). … However, they no longer assert the '919 patent against any Defendant." (citing D.I. 37; D.I. 64; 23-655 D.I. 26). So no infringement outcome exists for the '919 patent — the asserted patents that were actually litigated and invalidated in Delaware/on appeal are the '947 and '903 patents.

2. The headline 2025–2026 appellate activity did NOT involve the '919 patent. The Federal Circuit's Oct. 30, 2025 decision (Merck Serono S.A. v. Hopewell Pharma Ventures, Inc., Nos. 2024-1745, 2024-1746; and the parallel TWi appeal, No. 25-1463) affirmed PTAB obviousness holdings invalidating U.S. 7,713,947 and 8,377,903 — not 10,849,919 (https://www.cafc.uscourts.gov/opinions-orders/25-1463.OPINION.10-30-2025_2596136.pdf). The Jan. 22, 2026 rehearing denial likewise concerns those two patents. Because IPR2023-00482 (the only PTAB challenge to the '919 patent) settled pre-FWD, there is no PTAB decision on the '919 patent to appeal — consistent with my earlier finding of no CAFC docket for US 10,849,919.

3. Apotex's ANDA took a § viii carve-out on the '919 patent, not a Paragraph IV challenge. The FDA approval letter confirms Apotex filed a § 505(j)(2)(A)(viii) statement that the '919 patent "does not claim any indication or other conditions of use for which [it is] seeking approval." That is precisely why the '919 patent could not be asserted against Apotex and was dropped from 23-655.

4. Net effect on the '919 patent's status. The IPR settlement left the '919 patent unadjudicated and presumptively valid, and it remains Orange Book–listed (use code U-3411; nominal expiry Nov. 23, 2038). It was simply not the patent the generic challengers defeated on the merits.

Contradiction with the earlier-generated summary (flagged per your instruction)

My earlier summary stated, for 1:23-cv-00655, that "asserted claims of the '919 patent include at least claims 1, 14, and 27." The current, better-sourced record contradicts that as a present-tense assertion: the '919 patent was in the original complaint but was dropped (23-655 D.I. 26), and Apotex had filed only a § viii statement as to '919. The "claims 1, 14, 27" list most likely derives from the IPR2023-00482 petition (which challenged those claims), not from a live district court assertion. I have treated the court's own R&R as controlling.

Uncertainty flags

• I did not retrieve present-day PACER docket entries for each case this session; case-number/status details come from the Delaware court's published R&R, the FDA approval letter, the filed complaints, and secondary databases (DrugPatentWatch, Stanford NPE, Unified Patents). Case 22-974 (Accord) is confirmed only through its filed First Amended Complaint; I cannot confirm the precise date Accord stopped asserting '919.
• The consolidated Delaware cases were under a global stay pending the IPR appeals; I did not verify post-mandate activity (e.g., lifting of the stay or entry of judgment) as of April 26, 2026.
• I found no ITC § 337 action and no foreign litigation naming US 10,849,919 (foreign proceedings such as the Irish SPC appeal and the UK SPC case concern the European counterpart, not the US patent).

I'll search for the PTAB proceedings on this patent and fill in the details.

Let me confirm whether IPR2023-00482 is the only AIA trial on the '919 patent and get the termination details.

PTAB / AIA Trial Report — US Patent No. 10,849,919 ("10849919")

Cladribine regimen for treating progressive forms of multiple sclerosis — Dangond et al. — Ares Trading S.A.

⚠️ Contradiction flagged up front. The structured "PTAB proceedings on file" block states that the USPTO ODP API returns no AIA trial proceedings for this patent. That block is materially incomplete. The public record documents one AIA trial — IPR2023-00482 — filed 2023-02-10 and terminated on settlement 2023-08-16. The likely reason ODP omits it is that it was a pre-institution termination, so it never generated an institution decision or a Final Written Decision. Per the block's own instruction to flag proceedings "the ODP hasn't indexed yet," I treat IPR2023-00482 as canonical and verified against the Board's own papers.

Second contradiction flagged. The earlier-generated patent summary describes Ground 3 as running over "ClinicalTrials.gov + Schreiber + Giovannoni." The petition and the Patent Owner Preliminary Response both recite ClinicalTrials.gov + Montalban + Schreiber. Ground 3 did not rely on Giovannoni. Corrected below.

Proceedings overview

One AIA proceeding exists on US 10,849,919 — IPR2023-00482 — and it was terminated on settlement at the pre-institution stage, so the breakdown is: 0 active, 0 claims invalidated, 0 claims sustained by FWD, 1 settled, 0 institution denials. Bottom line for a defendant: the '919 patent has never been institution-tested, and no claim has ever been canceled or sustained by the Board. A generic defendant cannot point to a PTAB outcome as a shield — but it also faces a patent whose only PTAB challenge evaporated before the Board could opine, and whose sibling claims covering the same commercial regimen were held obvious and affirmed on appeal. The '919 is therefore untested, not hardened, and the Bodor/Stelmasiak roadmap from the sibling IPRs is the most promising invalidity template available.

IPR2023-00482 — Hopewell Pharma Ventures, Inc. v. Ares Trading S.A.

• Type: Inter Partes Review (IPR)
• Filed: 2023-02-10 (USPTO Patent Center / Docket Alarm; petition served with Exhibit 1001 = US 10,849,919 B2)
• Status: Terminated-Settled (verbatim from structured/third-party PTAB data); termination order entered 2023-08-16, styled "Termination Due to Settlement Before Institution of Trial."
• Judge panel: John G. New, Tina E. Hulse, and Timothy G. Majors, Administrative Patent Judges; Judge Majors authored the termination order. (Termination Decision, Paper 12)
• Real parties in interest: Petitioner — Hopewell Pharma Ventures LLC; Levy SPV, LLC; GLS Capital Partners Fund I, LP; GLS Capital Partners GP, LLC; GLS Capital, LLC (i.e., a litigation-financed / defensive-aggregator-style structure, not a generic manufacturer operating alone). Patent Owner — Ares Trading S.A., with Merck Serono S.A. and Merck KGaA identified as RPIs. (FWD in companion IPR2023-00480, Paper 62)
• Petition grounds (all § 103 obviousness; no § 102 or § 112 challenge):
  • Ground 1: Claims 1–6, 8, 9, 12, 14–16, 18–20, 24–27, and 34 obvious over Alvarez-Gonzalez (EX1009) + Giovannoni (EX1007).
  • Ground 2: Claims 11, 23, and 33 obvious over Alvarez-Gonzalez + Giovannoni + Montalban (EX1006).
  • Ground 3: Claims 1–6, 8, 9, 11, 12, 14–16, 18–20, 23–27, 30, and 33–34 obvious over ClinicalTrials.gov (EX1005, archived ONWARD pages) + Montalban (EX1006) + Schreiber (EX1008).
  • Petitioner's expert: declaration of Dr. Aaron Miller (EX1002–1003).
• Institution decision: None issued. The proceeding terminated before any § 314 decision. The Board expressly stated: "This Order does not constitute a decision on institution under 35 U.S.C. § 314, or a final written decision pursuant to 35 U.S.C. § 318(a)." The Patent Owner Preliminary Response (Paper 6, 2023-05-17) — filed by WilmerHale (Emily R. Whelan) — argued no reasonable likelihood of success, emphasizing the unmet need in progressive MS and that the art characterized SPMS cladribine studies as "uniformly disappointing." That POPR was never adjudicated.
• Final Written Decision: None. No claim-level verdict exists. No claim of the '919 has ever been canceled, confirmed, or construed by the Board.
• Settlement / termination: Joint Motion to Terminate filed 2023-08-15 (Paper 10) with a concurrently filed Joint Request to File Agreement as Business Confidential Information (Paper 11); Board authorization had issued 2023-08-09. The parties represented they had "reached an agreement to resolve all of their present dispute regarding the '919 patent" and that there were no other agreements made in connection with termination. The executed settlement agreement (Ex. 1070) was filed but sealed as business confidential under 35 U.S.C. § 317(b) / 37 C.F.R. § 42.74(c) — the terms are confidential and not public. Termination granted 2023-08-16 under § 317(a). (Joint Request, Paper 11)
• Appeal: None, and none possible. With no FWD, there is no appealable Board decision. No Federal Circuit docket exists for the '919 on this record. The 2025 Federal Circuit cladribine opinion (see context below) concerns the '947 and '903 patents only — not the '919.
• Defensive value: The '919 emerged untouched. Nothing was canceled, so an infringement theory built on claims 1, 27, or 34 is not sanction-bait — but by the same token you get zero estoppel and zero PTAB precedent to leverage. Because Hopewell settled pre-institution, § 315(e)(1) estoppel never attached against Hopewell or its privies, and no adverse patentability finding was ever made. Practically, this means the '919 is a clean slate: a future petitioner is free to run Alvarez-Gonzalez/Giovannoni/ClinicalTrials.gov/Montalban/Schreiber (or Bodor/Stelmasiak) without any prior Board credibility finding, favorable or unfavorable, in the record.

Context: sibling-patent IPRs that did reach judgment (NOT the '919)

These are different patents (different family, family 36227798 vs. the '919's family 64457023) and must not be cited as PTAB outcomes for the '919 — but they are the single most important signal for anyone assessing the '919's strength.

• Panel on the '947 FWD: Zhenyu Yang, Robert A. Pollock, and Timothy G. Majors (Majors authoring) — note Majors sat on both the '947 FWD and the '919 termination order.
• The Federal Circuit affirmed both FWDs on 2025-10-30 in Merck Serono S.A. v. Hopewell Pharma Ventures, Inc., 159 F.4th 10, holding the Bodor "six-line disclosure" was prior art "by another" under pre-AIA §§ 102(a)/(e) and that Bodor + Stelmasiak rendered all challenged claims obvious. (CAFC opinion PDF; A&O Shearman analysis)
• Merck's rehearing bid failed (Husch Blackwell press release confirming the Federal Circuit "declined to reconsider").
• Collateral effect: the Delaware court noted the parties dismissed all '919 claims against all defendants in Nos. 22-1365, 23-655, and 23-39, and imposed a global stay pending the '947/'903 IPR appeals. (D. Del. oral order, 2025-01-10)

Strategic summary

Claim status for the '919: everything is UNTESTED. No claim of US 10,849,919 has been canceled, and none has been sustained. There is no FWD, no certificate of cancellation, and no Federal Circuit mandate touching this patent. The only PTAB filing — IPR2023-00482 — challenged claims 1–6, 8, 9, 11, 12, 14–16, 18–20, 23–27, 30, and 33–34, and it died in settlement on 2023-08-16 before the Board could even decide whether to institute. If a demand letter cites claim 1, 14, 24, 27, 30, or 34, those claims are fully alive and enforceable (the patent is Active, with anticipated expiration 2038-11-23). The '919 was also dropped from the Delaware ANDA actions, which means the practical exposure today is a fresh assertion rather than a live one.

Estoppel landscape — this is the good news for a defendant. Because IPR2023-00482 terminated pre-institution, no statutory estoppel arose: § 315(e)(1) estoppel applies only after a final written decision, and there was none. Hopewell, its RPIs (Levy SPV, GLS Capital entities), and any privies are therefore not barred from re-challenging the '919 in a future IPR, and the § 315(e)(2) district-court estoppel that would have swept in "grounds reasonably could have raised" never triggered. Equally, because no Ground in the '919 petition was ever substantively evaluated by the Board, there is no issue-preclusion or estoppel from the '947/'903 FWDs that reaches the '919 — they are different patents with different claims (the '947/'903 claims recite multi-phase induction + maintenance dosing; the '919 claims recite a fixed dose per patient, per body weight, per treatment year — 1.75 mg/kg ± 0.2 — and expressly exclude ESPMS). The Bodor/Stelmasiak combination that killed the '947/'903 is the obvious starting prior art, and it is fully available against the '919. Caution: the § 315(b) one-year bar ran against the defendants served in the 2022–2023 Delaware complaints — a new petitioner must either be a later-served party or rely on a complaint served within the last year.

Pattern signals. (1) Same petitioner, multiple IPRs: Hopewell (bankrolled by GLS Capital, a litigation-funder RPI structure) filed a coordinated three-IPR campaign — IPR2023-00480/'947, IPR2023-00481/'903, IPR2023-00482/'919 — on the same day-cycle in early 2023. The two it litigated to judgment it won; the '919 one it settled. That asymmetry is telling: the strongest art (Bodor/Stelmasiak) was reserved for the '947/'903, while the '919 was attacked on materially weaker art (Alvarez-Gonzalez/Giovannoni/ClinicalTrials.gov) that the patent owner credibly rebutted in its POPR. (2) No defensive aggregator: despite the "Unified Patents Litigation Data" attribution on the Google Patents page, the petitioner was Hopewell/GLS Capital, not Unified Patents — the IPR2023-00482 entry on the front page is a generic PTAB case link, not a Unified-filed challenge. (3) The patent owner never had to defend a PTAB merits ruling on the '919, so there is no prosecution-disclaimer or claim-construction record from PTAB to exploit — but there is a D. Del. Markman record construing "maintenance period"/"induction period" in the sibling patents (Merck prevailed; the court refused to read in a "lower maintenance dose" requirement), which is a useful, if non-binding, signal for claim scope.

Recommended next steps

1. Do not plead the '919 as "invalidated." It isn't. Any representation that claims 1–34 were canceled by IPR is wrong; the only relevant Board paper is the pre-institution termination order (Paper 12, 2023-08-16), which states in terms that it is not an institution decision and not a § 318(a) FWD.
2. If you are a new (post-2023) defendant facing an '919 assertion, file your own IPR — the door is open. There is no estoppel and no prior Board finding; the § 315(b) clock runs from your service date. Build on the Bodor + Stelmasiak combination that the Federal Circuit affirmed on 2025-10-30, and stress why the '919's "fixed dose per patient, per body weight and per treatment year … 1.75 mg/kg ± 0.2" limitation is nonetheless obvious — mindful that the '947 panel held dose/duration are result-effective variables optimizable against lymphocyte suppression and that flat-to-weight-based conversion was obvious (a holding Merck unsuccessfully attacked on appeal). (CAFC opinion)
3. Mine the sealed record if you can. The '919 settlement agreement (Ex. 1070) is confidential, but its existence means Hopewell's '919 challenge was bought out — potentially teeing up a § 315(b)/real-party or privity question if a later petitioner is connected to Hopewell/GLS Capital. Conversely, the pre-institution settlement means no General Plastic-style "second bite" problem for a genuinely new petitioner.
4. If you are Hopewell/GLS Capital or a privy: confirm whether your settlement agreement contains a covenant or license affecting re-challenge, and note that, absent a FWD, you retain the ability to re-file — but check the agreement's own terms, which are not public.
5. If no assertion is pending: the absence of an institution decision on the '919 is itself the key datum. A well-asserted, blockbuster-drug patent that draws a funded IPR challenge and settles before institution signals the challenger lacked confidence in its art, not that the patent is bulletproof — the same challenger did go to judgment and win on the sibling patents with different art.

Bottom line: One IPR, settled pre-institution, zero claims canceled, zero claims confirmed. The '919 is an intact, untested patent (expiring 2038-11-23) that was dropped from the live Delaware actions — treat it as an open invalidity target, not a dead one, and not a validated one.

I'll research the assignment record for US 10,849,919, starting with the USPTO assignment data and corroborating sources.

Let me dig for the specific assignment records, reel/frame numbers, and correspondent details.

Let me pin down the assignment correspondent/reel data and inventor affiliations.

Assignment & Ownership Analysis — US 10,849,919 B2

Scope note on sources. The USPTO Patent Assignment Search (Assignment Center, https://assignmentcenter.uspto.gov/) did not yield machine-readable reel/frame records to me in this session. The assignment events (dates, conveyances, assignors/assignees) below are taken from the Google Patents "Legal Events" / "Reassignment" record for this patent (https://patents.google.com/patent/US10849919/en, "Reassignment" and "Change of Address" entries under Assignment) and corroborated by PTAB and district-court documents. I could not retrieve the reel/frame numbers or the recorded correspondent for the post-issuance assignments, and I will not fabricate them. That gap is flagged again in the timeline.

Inventors

Both names appear on the Application Data Sheet reproduced in the file-history exhibit (IPR2023-00482, Ex. 1004), listing assignee Merck Patent GmbH, Darmstadt, GERMANY, and correspondence at Grüneberg and Myers PLLC, Tysons, VA (rendered "Gnrneberg and Myers PLLC" in the OCR).

Pattern note (no anomaly): Neither inventor's residence or assignment record shows a departure from the Merck group in the 12 months after filing. Both executed an employee-invention assignment to the group's IP-holding company (Merck Patent GmbH) essentially at filing, and that company held the patent until the 2022 intra-group transfer. This is the classic big-pharma inventor→group-IP-company pattern, not a precursor to a portfolio fire-sale. I found no evidence of either inventor appearing as an assignor/assignee on any other assignment in this chain.

Original assignee

• Merck Patent GmbH (Frankfurter Strasse 250, 64293 Darmstadt, Germany) — named on the issued patent and the original assignee of record.
• Status: An intellectual-property holding company and indirect subsidiary of Merck KGaA. This characterization is not my inference — it is stated verbatim in Ares Trading S.A. v. Dyax Corp., No. 1:19-cv-02300 (D. Mass.): "Merck Patent GmbH ('Merck Patent'), is an intellectual property holding company and indirect subsidiary of Merck KGaA."
• Product embodying the claims: Yes. The patent is Orange Book–listed (use code U-3411) against MAVENCLAD (cladribine 10 mg tablets, NDA 022561, approved March 29, 2019). MAVENCLAD is marketed in the U.S. by EMD Serono, Inc., itself a wholly owned Merck KGaA subsidiary (Merck complaint, D. Del. 1:22-cv-00974, ¶¶20–22).
• Primary line of business / current status: Merck KGaA is a large, publicly traded operating life-science and electronics group (not a shell or a dissolved entity). Merck Patent GmbH remains active as the group's patent-holding vehicle. No bankruptcy, dissolution, or acquisition of the assignor occurred. The 2022 movement of this one patent to Ares Trading is a within-group reassignment, not a sale outside the corporate family.

Assignment timeline

1. ~Nov 2018 (executed, inferred from the Nov 23, 2018 filing) / recorded 2019-01-03 — Reel/frame NOT retrievable

• Conveyance: Assignment (recorded as "reassignment," type: Assignment)
• Assignor: Matthias Dotzauer; Fernando Dangond (joint inventors)
• Assignee: Merck Patent GmbH, Darmstadt, Germany
• Correspondent: Not retrieved for this recording. The prosecution correspondent of record on the ADS is Grüneberg and Myers PLLC, Tysons, VA; whether that firm filed the recording is unverified. No recurrence pattern can be asserted on the record available.
• Context: Standard employee-invention assignment to the employer's group IP-holding company — internal reorg / routine prosecution assignment, not a monetization event.

2. ~2022 (executed) / recorded 2022-09-02 — Reel/frame NOT retrievable

• Conveyance: Assignment ("reassignment")
• Assignor: Merck Patent GmbH
• Assignee: Ares Trading S.A. (Rue de l'Ourette 151, Zone industrielle de l'Ourettaz, 1170 Aubonne, Switzerland)
• Correspondent: Not retrieved. Flagged as an open item — if a single attorney/firm recurs on both the 2019 and 2022 recordings, that would need checking against NPE-asserter directories; I cannot confirm recurrence, so I make no finding.
• Context: Intra-group transfer within Merck KGaA. Ares Trading S.A. is not an arm's-length acquirer — the PTAB record states it "is an affiliate of the entity that owns Merck Serono, S.A.," and the ANDA complaint states it "is a wholly owned subsidiary of Plaintiff Merck KGaA" (¶4). Ares Trading was also the licensee/developer of the oral cladribine formulation under the 2003 IVAX–Ares Trading Product Development and License Agreement (IPR2023-00050, Ex. 2077), so it is the natural owner of an oral-dosing-regimen patent. Note the sibling patents '947/'903 stayed with Merck Serono SA — i.e., the group allocated this specific asset to the affiliate that developed the oral product.

3. (executed ~2023) / recorded 2023-02-06 — Reel/frame NOT retrievable

• Conveyance: Change of Address (not a transfer of title)
• Assignor/Assignee on the record: Ares Trading S.A. (self)
• Correspondent: Not retrieved.
• Context: Administrative address update only — no change in ownership. Consistent with a corporate address move within Aubonne (the 2022 complaint cites Rue de l'Ourette 151; earlier records cite "Château de Vaumarcus"/"Zone Industrielle de l'Ourettaz"). Benign.

Cross-reference: the patent also carries a Certificate of Correction recorded Oct. 25, 2022 (priority date and claim 6 dependency). That is a prosecution-side correction, not an assignment; it is captured in the previously generated sections and is not repeated here.

Timeline diagram

timeline
    title Ownership of US 10849919
    2017 : Priority application filed
    2018 : US application filed by inventors
    2019 : Assigned to Merck Patent GmbH
         : Mavenclad approved in US
    2020 : Patent granted
    2022 : Assigned to Ares Trading SA
         : First ANDA suits filed
    2023 : Ares Trading change of address
         : IPR2023-00482 settled

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT.
The only title transfer (recorded 2022-09-02) moved from Merck Patent GmbH to Ares Trading S.A., which is admitted in the pleadings to be "a wholly owned subsidiary of Plaintiff Merck KGaA" (D. Del. 1:22-cv-00974 ¶4) and is a co-plaintiff in the MAVENCLAD ANDA actions. It is an operating pharma affiliate (the oral-cladribine licensee/developer), not a licensing-only LLC, and its Aubonne, CH address is a Merck Serono campus address, not a registered-agent service. No "IP/Holdings/Ventures" single-purpose LLC appears anywhere in the chain.

2. Known asserter in the chain — NOT PRESENT.
Neither assignee (Merck Patent GmbH, Ares Trading S.A.) matches any entity on the Acacia / Marathon / Intellectual Ventures / IPNav / Wi-LAN / Conversant / Vringo / Pendrell / Round Rock / Spangenberg lists, nor any high-frequency-plaintiff entity surfaced by Unified Patents or RPX. Both are Merck KGaA operating-group entities.

3. Repeat correspondent across the chain — UNRESOLVED (not a finding).
I could not obtain the recorded correspondent for the 2019 or 2022 recordings, so recurrence cannot be established. The prosecution correspondent is Grüneberg and Myers PLLC (Tysons, VA) — a mainstream patent firm, not an NPE-linked filer. Because the signal is "recurrence," a single unverified appearance is not evidence; I mark this unresolved rather than present.

4. Cascading transfers — NOT PRESENT.
Two real title events over ~3.8 years (2019 → 2022), then an address-only entry (2023). No chain of LLCs, no sub-24-month serial hops, no shared correspondent address pattern.

5. Pre-litigation transfer — PRESENT AS TO TIMING, but NON-INDICATIVE.
The assignment to Ares Trading was recorded 2022-09-02, which falls between the first ANDA suit (Accord, D. Del. 1:22-cv-00974, filed July 25, 2022) and the Hopewell suit (1:22-cv-01365, filed Oct. 17, 2022) — i.e., within ~6 weeks of an infringement filing naming this patent. However, the recipient is the patent owner's own corporate affiliate that markets the drug through a sister company (EMD Serono), and it appears as owner/co-plaintiff on the complaint face. This is an intra-group IP reorganization timed to a Hatch-Waxman enforcement campaign, which is normal operating-company behavior — it is not the "arrange-the-chain-to-enable-assertion" setup that the signal is designed to catch.

6. Bankruptcy fire-sale — NOT PRESENT.
No Chapter 7/11, no 363 sale, no assignment to a liquidation vehicle. Merck KGaA is an operating, solvent, publicly traded group.

7. Privateering — NOT PRESENT.
No NPE asserts this patent on Merck's behalf. The asserters are the patent owner itself: Merck KGaA, Merck Serono SA, and Ares Trading SA as co-plaintiffs (D. Del. 1:22-cv-00974, 1:22-cv-01365, 1:23-cv-00039, 1:23-cv-00655). The patent-owner family also litigates its own IP directly (e.g., Ares Trading v. Dyax).

8. Defensive aggregator — NOT PRESENT.
The chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN. If anything, the inverse is true: Unified Patents-affiliated petitioner Hopewell Pharma Ventures challenged the patent (IPR2023-00482, filed Feb. 10, 2023; terminated–settled Aug. 16, 2023, no FWD), i.e., the patent is a target of defensive activity, not a member of a defensive pool.

Verdict

Operating-company assertion.

Justification: The complete post-issuance chain is a single intra-group assignment — recorded 2022-09-02 from Merck Patent GmbH to Ares Trading S.A., an entity the pleadings admit is a wholly owned Merck KGaA subsidiary and the developer/licensee of the oral cladribine product — followed only by an address-change recording (2023-02-06) that transfers no title. The patent is Orange Book–listed (U-3411) against MAVENCLAD, which Merck KGaA's EMD Serono actually sells, and every suit naming it is a Hatch-Waxman ANDA action against generic manufacturers (Accord, Aurobindo, Apotex/Hopewell). There is no shell entity, no known asserter, no fire-sale, and no defensive-aggregator terminus; the "operating company sues actual competitors" model is satisfied on the face of the complaint record.

Caveats / open items for verification at the Assignment Center:

• Reel/frame numbers and the recorded correspondent for the 2019-01-03 and 2022-09-02 recordings were not retrievable to me; confirm them directly (they would either close out signal #3 as "not present" or, if a single repeat attorney filed both, warrant a second look — though recurrence alone would still not defeat the operating-company verdict here).
• Execute dates for the 2019 and 2022 recordings are inferred from filing/pleading dates; only the recordation dates are sourced.

Verify at: https://assignmentcenter.uspto.gov/ (search patent number 10849919) · legal-events view at https://patents.google.com/patent/US10849919/en

I'll search for the specific patent and its cited prior art references.

Let me get the specific front-page citations and the IPR's prior-art exhibits.

Let me retrieve the actual front-page patent citation list and the related patents.

Prior Art Analysis — US Patent No. 10,849,919 (literal ID: "10849919")

0. Identifier discipline and one important false positive

Per the strict rule, I interpreted 10849919 literally as US 10,849,919 B2 ("Cladribine regimen for treating progressive forms of multiple sclerosis," App. No. 16/199,119, inventors Dangond & Dotzauer, filed Nov. 23, 2018, issued Dec. 1, 2020, priority Nov. 24, 2017 via provisional 62/590,442).

One search result — a Baidu document for the Kempe et al. natural-language patent (US 7,617,091) — displays "申请号：US10849919." That is an application-number artifact of a completely different, unrelated patent (natural-language processing). I have not treated it as, or returned it for, this patent. Flagging it explicitly because it is precisely the kind of near-number collision the operating rules forbid me to auto-correct into or out of.

1. Retrieval limitation (stated up front)

I was able to confirm the patent's identity, family, litigation, and PTAB history, but the Google Patents render I retrieved did not expose the front-page "(56) References Cited" table verbatim, and my web-search budget was exhausted before I could pull the USPTO PatentCenter/patentimages front page directly. Therefore:

• Section 2 lists patent documents cited within the '919 specification itself (these are the applicant-cited references I can ground verbatim), plus the one U.S. patent cited as prior art in the only PTAB challenge.
• Section 3 lists the decisive non-patent literature, which is where the real §102/§103 fight is.
• I have not fabricated the examiner-cited "U.S. Patent Documents" column. Where I am unsure of an exact title, filing date, or claim number, I say so.

2. Patent documents cited for / against US 10,849,919

3. The references that actually matter — IPR2023-00482 (Hopewell v. Ares Trading)

The only PTAB challenge to the '919 patent (IPR2023-00482, filed Feb. 10, 2023) was framed entirely as §103 obviousness, not §102 anticipation — an important signal that no single reference was believed to disclose every claim element. Its grounds and exhibits:

Grounds as filed: Ground 1 — claims 1–6, 8–9, 12, 14–16, 18–20, 24–27, 34 obvious over Alvarez-Gonzalez + Giovannoni; Ground 2 — claims 11, 23, 33 over Alvarez-Gonzalez + Giovannoni + Montalban; Ground 3 — claims 1–6, 8–9, 11–12, 14–16, 18–20, 23–27, 30, 33–34 over ClinicalTrials.gov + Schreiber + Montalban. (Note: the petition caption and the Patent Owner's Preliminary Response differ slightly in whether Montalban or Giovannoni is the third Ground-3 reference — I flag this rather than resolve it.) Status: Terminated–Settled Aug. 16, 2023, before institution and with no Final Written Decision.

The parallel '903-patent appeal (Fed. Cir. No. 22-470/related; Bodor/De Luca inventorship dispute) adds these §102-relevant materials: Bodor (WO 2004/087101 / Ex. 1022), Beutler (Ex. 1026), Romine (Ex. 1031), and Rice (Ex. 1018) — used there for the "by another" / §102(a) inventorship analysis, not in the '919 IPR. I note the exhibit-number overlap/dissonance between the '919 and '903 records as an uncertainty rather than asserting a clean crosswalk.

4. § 102 anticipation synthesis — claim by claim

Because the '919 patent's effective filing date (Nov. 24, 2017) is post-AIA, the governing novelty provisions are §102(a)(1) (publicly available before the EFD) and §102(a)(2) (U.S. patents/published applications effectively filed before the EFD). No reference I identified anticipates any independent claim 1, 14, 24, or 27, and I found no §102 challenge in the prosecution file or the IPR:

• Claim 1 (method of treating progressive MS selected from SPMS/PPMS/PRMS, expressly excluding ESPMS, via oral cladribine at a per-patient/per-body-weight/per-treatment-year fixed dose): The "progressive MS" element is only met by Alvarez-Gonzalez (2017), which lacks the fixed-dose element; the fixed-dose element is only met by Giovannoni (2010), which is RRMS-only. No single reference meets both → §102 fails; the art is a §103 combination.
• Claim 14 (2 treatment courses over 2 years; ~3.5 mg/kg cumulative; two treatment weeks, months 1 and 2; 10/20 mg/day): Giovannoni (2010) and US 8,377,903 disclose the regimen shape but for RRMS; Bodor/WO 2004/087101 discloses a strikingly similar 2-month-on/10-month-off shape but at 10 mg — again, no single-reference anticipation, §103 territory.
• Claim 24 (weight-banded 10 mg tablets, 2-month course + 10-month cladribine-free period): Closest to Bodor/ WO 2004/087101 and to Giovannoni's weight-based tablet tables, but neither discloses the combination with a progressive-MS indication → §102 fails.
• Claim 27 (cladribine for oral PPMS/SPMS treatment at 1.75 mg/kg ± 0.2 per treatment year over ≥2 years): The numeric fixed dose is a Giovannoni-derived (RRMS) teaching; the indication is Alvarez-Gonzalez-derived; → §103, not §102.

5. Uncertainty flags

1. I could not retrieve the USPTO front-page "(56) References Cited" table verbatim; Section 2 therefore reflects the references cited inside the '919 specification plus the one U.S. patent cited as prior art in the IPR, and is labeled as such — it is not a substitute for the examiner's citation column.
2. Exact titles/dates for US 5,506,214, EP 626853 B1, US 5,208,327, EP 173059, and WO 96/19229/19230 were not independently re-verified in this session.
3. All §102 characterizations are statutory-provision mappings I have drawn; I found no PTAB or court anticipation holding on this patent (the sole IPR settled pre-institution, and I identified no CAFC 2026 docket for US 10,849,919).
4. Exhibit-number crosswalks between the '919 IPR and the related '903 appeal are not clean in my sources; treat the Bodor/Beutler/Romine/Rice exhibit numbers as belonging to the '903 record unless independently confirmed.

Bottom line: the most relevant prior art for US 10,849,919 is Alvarez-Gonzalez (2017) for the progressive-MS indication and Giovannoni (2010) for the fixed-dose regimen, combined in the only PTAB challenge; Bodor/WO 2004/087101 is the most probative single dosing-regimen reference. None of them, individually or as I could document, discloses every element — which is why the record is a §103 obviousness record, not a §102 anticipation record.

I'll research the prior-art record for this patent before analyzing.

Significant new information has surfaced that contradicts the earlier summary. Let me verify the PTAB/CAFC record and the claim language.

Let me get the actual granted claim text and the ONWARD study disclosures.

Obviousness Analysis — U.S. Patent No. 10,849,919 under 35 U.S.C. § 103

Analyst note (current date: April 26, 2026). Interpreted literally, US 10849919 = US 10,849,919 B2. Before the § 103 analysis I must flag that the freshest search results correct and materially extend the earlier-generated summary.

A. Corrections / additions to the earlier record (flagging contradictions as instructed)

Scope limitation of this analysis: the fetched Google Patents text does not contain the enumerated "References Cited" list (it shows only the prior-art keywords: cladribine, treatment, tablets, administered, multiple sclerosis). I therefore reconstruct the operative prior-art set from (i) the references the '919 specification itself cites, and (ii) the references actually relied upon in IPR2023-00482 (Exs. 1005–1009) as retrieved. Do not treat my reference list as the face-of-patent citation list.

B. Governing law and prior-art status

The '919 has an effective filing date of Nov. 23, 2018, claiming benefit of provisional 62/590,442 (Nov. 24, 2017) — a date the Oct. 25, 2022 certificate of correction fixed in the specification (from "Nov. 24, 2018" to "Nov. 24, 2017"). It is therefore an AIA patent; §§ 102/103 as amended apply.

Two consequences that matter enormously:

1. The "by another" / In re Land fight that Merck lost on the siblings largely evaporates. The '947/'903 defeat turned on pre-AIA § 102(a)/(e) "by another" and In re Land, 368 F.2d 866 (CCPA 1966) (Nat'l L. Rev.). Under AIA § 102(b)(1)(A)/(b)(2)(A), the grace-period exceptions are narrower and inventor-identity-driven; there is no § 102(b) exception that rescues a published patent from § 102(a)(1) art status. That makes the analysis against the '919 easier in one respect but requires checking a different set of exclusions (see below).
2. Merck's own earlier patents are prior art against the '919. US 7,713,947 (granted 2010) and US 8,377,903 (granted 2013) are § 102(a)(1) printed publications. The § 102(b)(2)(C) common-ownership exception applies only to § 102(a)(2) art, not to § 102(a)(1) publications, so it does not remove them. Their claims were held unpatentable; their disclosures remain fully available as § 103 art.

Exclusions a petitioner must check (the '919's real § 102(b) exposure):

• Alvarez-Gonzalez (Mar. 17, 2017) falls inside the one-year grace period relative to Nov. 24, 2017. If it were authored by Dangond, Dotzauer, or another joint inventor (unlikely — it is a Spanish clinical case series), § 102(b)(1)(A) could disqualify it. Verify authorship before relying on it.
• Montalban (Apr. 4, 2016) and ClinicalTrials.gov ONWARD (captured 2014) are outside the grace period — no § 102(b) escape.
• If the provisional fails to provide § 112 support for the ESPMS exclusion / fixed-dose limitations, the effective date slides to Nov. 23, 2018 and additional 2018 art (e.g., the Mavenclad EMA approval of Aug. 2017 and its label, and the 2018 downstream publications) joins the set. The EMA approval is already prior art on either date.

POSA. A treating neurologist or clinical pharmacologist with an M.D. and 5+ years of MS clinical-trial experience, familiar with the McDonald criteria, the Lublin-Reingold course definitions, EDSS, annualized relapse rate, MRI lesion metrics, and the cladribine literature (Bodor, Stelmasiak, Grieb, Beutler, Rice, Giovannoni) — consistent with Dr. Miller's framing in Ex. 1002.

C. The prior-art set (verified)

D. The independent claims, elementized

Based on the verified claim-1 preamble, the specification's Sections 1–27, the Orange Book use code, and the IPR petition:

1. Indication: treating a progressive form of MS selected from SPMS, PPMS, PRMS, excluding ESPMS (claim 1); optionally limited to PPMS and/or SPMS (claims 4/5/6, 27).
2. Route: oral cladribine (tablets or capsules, 10 mg; claim 24).
3. Dose metric: a "fixed dose" calculated per patient, per body weight, and per treatment year, in the range 1.5–4.0 mg/kg/yr (claim 1), preferably 1.75 mg/kg ± 0.2 (claims 3, 27) → 3.5 mg/kg over two adjacent years.
4. Temporal architecture: two treatment weeks, one at the start of month 1 and one at the start of month 2 of each treatment year; 10 or 20 mg/day for 4–5 days per week (claim 14); then a 10-month cladribine-free period.
5. Two adjacent treatment years (claims 14, 27), optionally with IFN-β co-therapy (claims 21/22) and ages 18–65 (claim 20).
6. Claim 24: tablet-number-by-weight-band table (e.g., 40–<50 kg → 4 then 4 tablets; 100–<110 kg → 10 then 9 tablets).

Every one of elements 2–6 is a numerical/dosing-schedule limitation; only element 1 (patient population) is a therapeutic-use limitation. That structural fact drives the whole obviousness case: under KSR, In re Peterson, and In re Woodruff, a claimed range that overlaps or sits adjacent to a disclosed range is obvious absent evidence of criticality — and under In re Montgomery / Allergan v. Sandoz, a method-of-treatment claim is ordinarily obvious where the art teaches the drug and the condition.

E. Ground 1 — Bodor + Stelmasiak + Alvarez-Gonzalez (+ Giovannoni for weight-banding)

This is the strongest ground because it is the same combination (Bodor + Stelmasiak) that the Board and the Federal Circuit found sufficient to invalidate the sibling regimen claims.

Element mapping

Motivation to combine (articulable, evidence-backed):

• Same drug, same disease, same mechanism. Bodor and Stelmasiak both treat MS with cladribine; there is no field-of-use barrier to combine.
• Bodor holds itself out as the improved oral product (bioavailability 39–43%, clinical studies in MS patients, explicit dosing schedule) — a direct design incentive to adopt its schedule.
• MS is chronic, incurable, and progressive; the Board found this supplies the reason to repeat Bodor's induction (Fed. Cir. slip op. at 49–51, quoting J.App'x 49, 51). Stelmasiak supplies a concrete retreatment scheme with clinical benefit — the "maintenance"/second-course limitation.
• Safety-driven dose selection. Both the '919's own specification and Giovannoni's data push toward the lower cumulative dose (3.5 mg/kg vs. 5.25 mg/kg), making the 1.5–4.0 mg/kg/yr range the predictable, obvious selection (KSR; In re Peterson).
• Weight-based fixed dosing is the routine, expected way to administer a per-kg cytotoxic — and Giovannoni actually implemented it in a phase III program with 10-mg tablets, giving POSAs a ready blueprint. Stelmasiak's statement that response was not correlated with mg/kg is a correlation observation, not a teaching that weight-banding is inoperative or would be expected to fail; a teaching-away requires the latter (In re Fulton; In re Gurley) — precisely the argument that failed for Merck in the '903 IPR (see the Lublin declaration's §§ VI.B.2, which the Board rejected, Ex. 2051).
• The progressive-MS population limitation is supplied by Alvarez-Gonzalez (direct) and independently by Rice 2000 — which the '919's own specification concedes was "positive on the significant reduction of MRI-measured brain lesions" in PP/SP patients. Applicant admissions in the specification are usable as § 103 evidence (In re Nomiya).

Reasonable expectation of success. Oral cladribine was in phase III for MS; its lymphocyte-depleting PD was characterized; Bodor reported human PK; Stelmasiak reported clinical benefit; Giovannoni reported a successful phase III. Predictability of "a pharmaceutically effective amount administered on a known schedule to a known MS population" is high. The law requires a reasonable expectation, not certainty (Amgen v. Sandoz).

Claim-by-claim: this ground reaches claims 1–9, 11–12, 14–16, 18–20, 23–27, 33–34 on the petition's own mapping; the only claims requiring Montalban (11, 23, 33) are those demanding the IFN-β-add-on framing.

F. Ground 2 — Giovannoni (CLARITY) + ClinicalTrials.gov ONWARD + Montalban + Schreiber + Alvarez-Gonzalez

This is the combination the petitioner's Grounds 1/3 in IPR2023-00482 actually advanced, and it is the better fit for claims 14 and 24 and for claim 27.

• Giovannoni supplies elements 2–5 wholesale: oral 10-mg tablets, weight-banded dosing to deliver 1.75 mg/kg/yr (3.5 mg/kg cumulative over 96 weeks), two treatment courses per year, 10/20 mg/day, 4–5 days/week, and the second-year course. Claim 24's tablet-count table is essentially Giovannoni's supplementary-appendix band table.
• ClinicalTrials.gov ONWARD supplies the indication bridge: a cladribine study expressly recruiting SPMS patients with active disease (i.e., not "early SPMS"), plus the add-on IFN-β protocol → dependent claims 21/22.
• Montalban supplies the ONWARD efficacy results in that SPMS-inclusive population.
• Schreiber supplies confirmation that oral cladribine is a recognized MS therapy, closing any "would a POSA have considered oral dosing?" gap.
• Alvarez-Gonzalez supplies the direct progressive-MS teaching.

Motivation: once CLARITY demonstrated safety/efficacy of the exact 3.5 mg/kg-over-2-years weight-banded regimen, and ONWARD was already enrolling SPMS patients, expanding the labeled population from relapsing MS to progressive MS in the same regimen (rather than optimizing a new one) is the definition of an obvious, predictable variation. There is no new formulation, no new route, no new dosing architecture, and no new mechanism — only a new row in the indication column.

Note on a record discrepancy. The petition styles Ground 3 as "ClinicalTrials.gov, Schreiber, and Giovannoni," while the POPR headings describe it as "ClinicalTrials.gov, Schreiber, and Montalban." The discrepancy is immaterial for this analysis because Montalban (ONWARD results) and ClinicalTrials.gov (ONWARD protocol) are the same study, and Giovannoni/ClinicalTrials.gov-Schreiber each independently supply the dose limitation. Flagging it as a drafting inconsistency in the IPR record.

G. Ground 3 — Merck's own prior patents + Rice 2000 + Grieb

A petitioner should also plead US 7,713,947 + US 8,377,903 + Rice 2000 (+ Grieb) as a standalone or cumulative ground.

• The '947/'903 disclosures describe the induction → cladribine-free → maintenance → cladribine-free oral cladribine regimen in mg/kg terms (representative '947 claim 36: induction 2–4 months at ~1.7–3.5 mg/kg, 8–10 months off, maintenance 2–4 months at ~1.7 mg/kg, then drug-free).
• Because these patents are § 102(a)(1) prior art against the '919 and were adjudicated obvious over Bodor + Stelmasiak at the PTAB and on appeal, they function as a self-inflicted admission that the regimen architecture was known and obvious. The only thing the '919 adds is the patient-population label.
• Rice 2000 teaches cladribine in PP and SP MS (with positive MRI-lesion results); Grieb 1995 teaches oral cladribine in monthly 5-day courses. Combined, they supply both the population and the schedule.

This ground is valuable less as an independent killer than as cumulative reinforcement: the patentee cannot simultaneously argue that the regimen was the '947/'903 inventors' discovery and that applying it to a progressive-MS population was a separate, non-obvious invention.

H. Claim-by-claim assessment

I. The patentee's rebuttal — and why the 2025 Federal Circuit decision cuts against it

Merck's expected counter-case (per the POPR and the Lublin declaration in the sibling IPR):

1. Teaching away / skepticism. Rice 2000 failed on clinical endpoints; PROMISE (glatiramer acetate), OLYMPUS (rituximab), and INFORMS (fingolimod) "did not reach meaningful clinical endpoints"; the '919 specification itself quotes the art calling SPMS studies "uniformly disappointing."
2. No motivation to use weight-based dosing — Stelmasiak states response was not related to mg/kg.
3. Unexpected results. The ONWARD SPMS subgroup showed an 89% reduction in qualifying relapses vs. 50% in RRMS patients.
4. Long-felt need — no approved oral therapy for progressive MS.
5. Hindsight — the references must be combined with knowledge of the claims.

Why these are unlikely to carry the day:

• The same objective-indicia package (skepticism, unexpected results, long-felt need, nexus — argued by Dr. Lublin at length, Ex. 2051 §§ IX.A–D) was presented in the '903 IPR and rejected; the Board found the claims obvious and the Federal Circuit affirmed on Oct. 30, 2025. That is the single most important predictive data point for the '919.
• Rice 2000 is an admission, not a shield: the '919 specification concedes it was "positive on the significant reduction of MRI-measured brain lesions."
• Failure of other agents is not teaching away from cladribine. The ONWARD investigators themselves chose to enroll SPMS patients, and Alvarez-Gonzalez affirmatively used cladribine in progressive MS.
• The 89% vs. 50% figure is from the ONWARD trial itself — i.e., the patentee's own prior-art-adjacent study (protocol on ClinicalTrials.gov in 2013–14; results published April 2016, before the Nov. 2017 priority date). Data generated before the priority date cannot ordinarily serve as evidence of unexpected results attributable to the claimed invention.
• The negative ESPMS limitation is a drafting artifact, not an inventive step. Merck split the SPMS continuum between its own '903 claims ("RRMS or early SPMS") and the '919's commercial use code ("TREATING NON-EARLY SPMS… 1.75 ± 0.2 MG/KG … MONTHS 1 AND 2 IN EACH OF 2 ADJACENT TREATMENT YEARS," DrugPatentWatch). Carving an adjacent sub-population out of a known continuum, with no evidence of a critical threshold or a different mechanism, is a classic obviousness scenario (In re Kao; In re Woodruff).

J. Bottom line, confidence, and residual gaps

Conclusion. Claims 1–27 and 30, 33, 34 of US 10,849,919 are, on the present record, more likely than not obvious under § 103. The single most efficient two-reference theory is Bodor (WO 2004/087101) + Stelmasiak (1998) — which literally discloses the claimed months-1-and-2 dosing weeks and the 10-month cladribine-free period and was sufficient to invalidate the sibling '947/'903 claims — combined with Giovannoni (CLARITY) for the fixed weight-based 1.75 mg/kg/yr dose and Alvarez-Gonzalez 2017 and/or ClinicalTrials.gov ONWARD + Montalban 2016 for the progressive-MS (non-early SPMS) population. The KSR-sanctioned motivations are: same drug/same disease; chronic, relapsing/remitting-progressive disease requiring retreatment; the known, safety-driven preference for the lower cumulative dose; and the routine clinical practice of weight-band dosing for per-kg cytotoxics.

Confidence: high for claims 14–24 and 27 (the regimen claims — the art maps essentially limitation-for-limitation); moderate-high for claim 1, which depends on construction of the "does not include ESPMS" negative limitation; no assessment possible for claims 33 and 34 because their verbatim text is not in the sources I could retrieve.

Explicit gaps / caveats:

1. No PTAB or court has ruled on the '919's validity. IPR2023-00482 settled pre-institution (Aug. 16, 2023), so there is no FWD and no appellate decision on the '919. The invalidity case is transferable but not adjudicated.
2. The face-of-patent "References Cited" list was not present in the fetched page text; I could not verify which references the examiner actually applied or distinguished. A complete file-wrapper review (Ex. 1004, the '919 prosecution history, is listed in the IPR but was not retrieved) is required before finalizing a ground.
3. Alvarez-Gonzalez sits inside the AIA grace period (Mar. 17, 2017). Verify authorship before relying on it; if Dangond or Dotzauer authored it, § 102(b)(1)(A) may disqualify it, though Ground 2 does not need it.
4. Provisional 62/590,442 support has not been verified. If the provisional does not support the fixed-dose and ESPMS-exclusion limitations, the effective date slips to Nov. 23, 2018, enlarging the art set (including the Aug. 2017 EMA Mavenclad approval and label).
5. Claims 33 and 34 remain undetermined. The '919's claim set (claims 30, 33, 34 challenged) is not fully reproduced in any source I retrieved; a full claim printout from the granted patent is a prerequisite.
6. A further Merck filing appears in December 2025 (fedcircuitblog posting); I could not verify whether it is a rehearing petition, a certiorari petition, or a reproduction of the opinion. Its disposition could affect the precedential weight of the Oct. 30, 2025 Merck Serono v. Hopewell "by another" holding — though that holding governs the pre-AIA siblings, not the AIA-governed '919.

Practical takeaway: the '919's viability turns almost entirely on (a) claim construction of the ESPMS carve-out and (b) whether a fact-finder credits the ONWARD SPMS data as unexpected results. Given that the identical objective-indicia package was rejected in the sibling proceedings and affirmed by the Federal Circuit on Oct. 30, 2025, a § 103 challenge built on Bodor + Stelmasiak + Giovannoni + ONWARD/Alvarez-Gonzalez should be viewed as a strong candidate for institution and, on a full record, for a finding of unpatentability.